Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase I/II, open-label, dose-escalation study is to evaluate an
investigational monoclonal antibody administered as a first-line therapy to patients with
acute, Grade II, III, or IV graft-versus-host disease (GVHD). Patients will be eligible for
enrollment within 24 hours of beginning standard steroid treatment. The research is being
conducted at up to 10 clinical research sites in the US.